论文部分内容阅读
目的:观察澳沙利铂联合表阿霉素及5-FU、醛氢叶酸(EOF方案)对晚期胃癌的近期疗效及安全性。方法:入选者为病理证实的晚期胃腺癌患者。化疗方案:表阿霉素50mg/m2静脉注射,d1,澳沙利铂85mg/m2静脉滴注2小时,d1,甲酰四氢叶酸200mg/m2静脉滴注2小时,d1～3,5-FU500mg/m2持续静脉泵入22小时,d1～3,每三周重复,至少完成3个周期判效。结果:共计37例入组,36例可评价疗效及不良反应。其中男28例,女8例,中位年龄52岁(32～75岁),治疗总周期数130周期,平均3.6周期。CR2例(5.6%),PR13例(36.1%),总缓解率RR41.7%,SD47.2%(17/36),PD11.1%(4/36),KPS评分提高20分以上者38.9%(14/36),CBR改善者占50.0%。Ⅲ°/Ⅳ°主要不良反应为中性粒细胞减少19.4%(7/36),血小板减少11.1%(4/36),贫血8.3%(3/36),恶心呕吐8.3%(3/36),腹泻2.8%(1/36),感觉神经异常11.1%(4/36)。结论:本研究显示,此方案治疗晚期胃癌疗效肯定,不良反应能够耐受。
Objective: To observe the short-term efficacy and safety of combined use of oxaliplatin and epirubicin, 5-FU and EOF in advanced gastric cancer. Methods: The selected patients with pathologically confirmed advanced gastric adenocarcinoma. Chemotherapy: epirubicin 50mg / m2 intravenous injection, d1, oseltallohline 85mg / m2 intravenous infusion of 2 hours, d1, leucovorin 200mg / m2 intravenous infusion of 2 hours, d1 ~ 3,5- FU500mg / m2 continuous intravenous infusion of 22 hours, d1 ~ 3, repeated every three weeks, at least 3 cycles to complete the judgment. Results: A total of 37 cases were enrolled and 36 cases were evaluated for efficacy and adverse reactions. There were 28 males and 8 females with a median age of 52 years (32-75 years). The total number of cycles was 130, with an average of 3.6 cycles. CR2 cases (5.6%), PR13 cases (36.1%), total remission rate RR41.7%, SD47.2% (17/36), PD11.1% (4/36), KPS score increased more than 20 points 38.9 % (14/36), improvement of CBR accounted for 50.0%. The main side effects of Ⅲ ° / Ⅳ ° were neutropenia 19.4% (7/36), thrombocytopenia 11.1% (4/36), anemia 8.3% (3/36) and nausea and vomiting 8.3% (3/36) , Diarrhea 2.8% (1/36), sensory nerve abnormalities 11.1% (4/36). Conclusion: This study shows that this regimen is effective in treating advanced gastric cancer and its adverse reactions can be tolerated.